The Role of ErbB3 and its Binding Partners in Breast Cancer Progression and Resistance to Hormone and Tyrosine Kinase Directed Therapies

The MEK/MAPK pathway is involved in the

The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib

✍ Nicola Normanno; Antonella De Luca; Monica R. Maiello; Manuela Campiglio; Maria 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 287 KB 👁 1 views

## Abstract We investigated the role of the MEK/MAPK pathway in the sensitivity/resistance of breast carcinoma cells to the EGFR tyrosine kinase inhibitor gefitinib (IRESSA). We assessed the effects of gefitinib on the growth of three breast cancer cell lines that showed high (SK‐Br‐3; IC~50~ 4 µM)